InflaRx (IFRX) Stock Forecast & Price Target

InflaRx is viewed positively because it has a differentiated C5a/C5aR platform with multiple shots on goal, led by GOHIBIC (vilobelimab) and izicopan, and the core biology is compelling since C5a is a potent inflammatory amplifier that drives chemotaxis, neutrophil activation, endothelial injury, and cytokine release across autoimmune and inflammatory diseases. The investment case is strengthened by izicopan’s apparent best-in-class profile versus Tavneos, including no serious adverse events or treatment-emergent adverse events in more than 180 subjects dosed, superior PK/PD and bioavailability, more convenient dosing with the potential for once-daily maintenance, and survey data showing roughly 92% of prescribers would increase use of the class for a safer, faster-acting, once-daily oral C5aR inhibitor while ~70% remain concerned about Tavneos hepatotoxicity and liver monitoring burden. Financially and commercially, the company has meaningful upside from AAV alone with base-case peak sales modeled at about $1.96B worldwide in 2044, but it is not expected to be profitable for several years and may need additional capital, making the outlook fundamentally driven by the combination of a large unmet need, favorable physician feedback, and a potentially advantaged replacement for a product facing regulatory and safety headwinds.

InflaRx is a clinically promising but commercially fragile biotech, because its lead assets remain dependent on proving clear differentiation in crowded inflammatory markets where established standards of care already achieve high remission rates and recurring relapse still requires entrenched background immunosuppression. The company’s own narrative underscores that vilobelimab has effectively wound down active commercialization, generated only about €29K of revenue against roughly €18.0M of SG&A expense in 2025, and therefore contributes little near-term operating leverage while any U.S. or EU commercial effort would likely require a partner. Even though the balance sheet is supported by €39.8M in cash and marketable securities at the end of 1Q26 plus an approximately €127M offering that is expected to fund runway through 2029, the investment case remains challenged by dependence on uncertain trial readouts, regulatory outcomes, and the need to compete against products like Tavneos, which has already reached $643M in 2025 global sales and about a $600M annualized run-rate in 2Q26.